Business Context and Reporting Period
Company: Prestige Brands Holdings, Inc. (and subsidiary Prestige Brands International, LLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: The Company markets, sells, and distributes over-the-counter (OTC) drugs, personal care, and household cleaning brands to mass merchandisers, drug stores, and supermarkets primarily in the United States. The Company completed an Initial Public Offering (IPO) in February 2005.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2005 |
Three Months Ended Sep 30, 2004 (Restated) |
Six Months Ended Sep 30, 2005 |
Six Months Ended Sep 30, 2004 (Restated) |
|---|---|---|---|---|
| Net Sales | $73,320 | $79,932 | $136,748 | $138,612 |
| Gross Profit | $37,796 | $42,017 | $72,300 | $67,634 |
| Gross Margin % | 51.5% | 52.5% | 52.9% | 48.8% |
| Operating Income | $20,827 | $26,812 | $39,084 | $34,434 |
| Net Income | $7,374 | $9,902 | $13,303 | $2,811 |
| Diluted EPS | $0.15 | $0.23 | $0.27 | $(0.19) |
| Cash from Operations (6mo) | $24,530 (2005) vs $26,405 (2004) | |||
| Total Debt (Long-term + Current) | $493,495 (Sep 30, 2005) | |||
| Cash and Equivalents | $27,585 (Sep 30, 2005) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9.0% ($6.6 million) in the quarter and 1.4% ($1.9 million) in the six-month period compared to the prior year. All three segments (OTC Drugs, Personal Care, Household Cleaning) experienced declines in the quarter, driven by softness in the wart remover category (Compound W), liquid bandage category (New Skin), and nail polish remover (Cutex).
- Profitability: Operating income decreased 22.3% in the quarter due to lower sales and a $1.8 million increase in advertising and promotion spending. However, for the six-month period, Net Income increased significantly to $13.3 million from $2.8 million, largely due to a $7.6 million loss on extinguishment of debt in the prior year period that did not recur.
- Restatement of Prior Periods: The Company announced a restatement of financial results for fiscal years 2003, 2004, and 2005, and quarters ended June 30, 2005 and 2004. Adjustments were made for revenue recognition (shifting from shipment to delivery/FOB destination), classification of trade promotions (reclassifying from expense to revenue reduction), deferred income taxes, and earnings per share calculations.
- Interest Expense: Net interest expense decreased 20.0% in the quarter and 41.5% in the six-month period due to the reduction of indebtedness following the February 2005 IPO.
Guidance, Outlook, Risks, and Contingencies
- Internal Control Material Weaknesses: Management concluded that disclosure controls and procedures were not effective as of September 30, 2005. Material weaknesses were identified regarding revenue recognition, classification of trade promotions, deferred income taxes, and EPS computation. A remediation plan is underway.
- Legal Proceedings:
- Securities Class Action: A consolidated putative securities class action lawsuit was filed in August 2005 alleging false/misleading statements regarding declining product demand and product withdrawals. A similar action was filed in Illinois. Management believes allegations are unfounded.
- Product Liability: Two class action lawsuits regarding the efficacy of dextromethorphan in Little Remedies products were dismissed in September 2005.
- Trade Dress: An appeal is pending regarding a trade dress infringement lawsuit involving the ARTHx trademarks (previously sold by the Company).
- Subsequent Acquisitions: Following the period end, the Company acquired the Chore Boy line of household cleaning products for $22.3 million and Dental Concepts, LLC for $30.6 million.
- Liquidity: The Company has $60.0 million available under its Revolving Credit Facility and believes cash flows and borrowings will meet obligations for the next 12 months.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the financial restatement on historical performance and the timeline for filing the amended 10-K/A.
- Internal Controls: Monitor the progress of the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Legal Exposure: Track the status of the consolidated securities class action lawsuit and potential liability exposure.
- Brand Performance: Assess the sustainability of sales declines in key legacy brands (Compound W, New Skin, Cutex) versus growth in newer acquisitions (Little Remedies, Chloraseptic).
- Debt Covenants: Confirm continued compliance with financial covenants (leverage, interest coverage) under the Senior Credit Facility, especially given the recent sales softness.